Risk of hepatitis B reactivation and cytomegalovirus related infections with Mogamulizumab: A retrospective study of international pharmacovigilance database
Authors:
Open Access
- 1 November 2020
- journal article
- research article
- Published by Elsevier in eClinicalMedicine
- Vol. 28, 100601
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: A prospective studyHepatology, 2013
- How I treat adult T-cell leukemia/lymphomaBlood, 2011
- Phase I Study of KW-0761, a Defucosylated Humanized Anti-CCR4 Antibody, in Relapsed Patients With Adult T-Cell Leukemia-Lymphoma and Peripheral T-Cell LymphomaJournal of Clinical Oncology, 2010
- Quantitative signal detection using spontaneous ADR reportingPharmacoepidemiology and Drug Safety, 2009
- Rituximab-related viral infections in lymphoma patientsLeukemia & Lymphoma, 2007
- Antiviral prophylaxis in patients with haematological malignancies and solid tumours: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Oncology (DGHO)Annals of Oncology, 2006
- Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sézary syndromeBlood, 2003
- Determinants of signal selection in a spontaneous reporting system for adverse drug reactionsBritish Journal of Clinical Pharmacology, 2001
- Introducing MEDWatch. A new approach to reporting medication and device adverse effects and product problemsJAMA, 1993
- Diagnostic criteria and classification of clinical subtypes of adult T‐cell leukaemia‐lymphomaBritish Journal of Haematology, 1991